Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)

Cybersecurity and Cybercrime Combatting Culture for African Police Services

Part 3: Peace and WarInternational audiencePolice forces are responsible to investigate cybercrimes and to protect their own assets from cybersecurity attacks. The majority of police forces find it difficult to fulfil their responsibilities in this regard in the face of constrained funding, a lack of awareness and training amongst law enforcement staff, the growing number of cybercrime incidences, and outdated or insufficient technology and infrastructure. Even if police forces are able to install technical controls to counter cyber threats, their staff members’ cyber behaviour may be a weak link in the cybersecurity chain and will probably not have sufficient training. The cultivation of a cybersecurity culture has been shown to be the best approach to address human behaviour in the cyber domain. There are several frameworks and other resources available for an organisation to cultivate a cybersecurity culture but the organisational culture in law enforcement agencies is different than that in other organisations. The cyber behaviour, cybercrime investigation skills, training and education of police force members require customised strategies and research. African police forces find it particularly difficult to deal with these challenges due to a lack of funding and a shortage of cybersecurity capability and capacity. This paper presents guidelines for African police forces to formulate strategies and plans to train and educate their members and to foster an organisational cybersecurity and cybercrime combatting culture

Focal brain damage protects against post-traumatic stress disorder in combat veterans

Post-traumatic stress disorder (PTSD) is an often debilitating mental illness that is characterized by recurrent distressing memories of traumatic events. PTSD is associated with hypoactivity in the ventromedial prefrontal cortex (vmPFC), hyperactivity in the amygdala and reduced volume in the hippocampus, but it is unknown whether these neuroimaging findings reflect the underlying cause or a secondary effect of the disorder. To investigate the causal contribution of specific brain areas to PTSD symptoms, we studied a unique sample of Vietnam War veterans who suffered brain injury and emotionally traumatic events. We found a substantially reduced occurrence of PTSD among those individuals with damage to one of two regions of the brain: the vmPFC and an anterior temporal area that included the amygdala. These results suggest that the vmPFC and amygdala are critically involved in the pathogenesis of PTSD.Published versio